Some of the best links we picked up around the internet
Fate Therapeutics announced this week that enrolment is underway for a Phase 1 trial of FT-825/OMO-8250 in advanced HER2-expressing solid tumours.
In this clinical trial roundup, we look at ongoing trials of gene-edited therapies for cancers of the gastrointestinal tract.
In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...